These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 7686450)
1. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Del Vecchio S; Stoppelli MP; Carriero MV; Fonti R; Massa O; Li PY; Botti G; Cerra M; D'Aiuto G; Esposito G Cancer Res; 1993 Jul; 53(13):3198-206. PubMed ID: 7686450 [TBL] [Abstract][Full Text] [Related]
2. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178 [TBL] [Abstract][Full Text] [Related]
3. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104 [TBL] [Abstract][Full Text] [Related]
5. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521 [TBL] [Abstract][Full Text] [Related]
6. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795 [TBL] [Abstract][Full Text] [Related]
7. Vitronectin binding to urokinase receptor in human breast cancer. Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812 [TBL] [Abstract][Full Text] [Related]
8. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients]. Zhou Q; Liang LJ; Peng BG; Zhen YY Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916 [TBL] [Abstract][Full Text] [Related]
9. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945 [TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751 [TBL] [Abstract][Full Text] [Related]
11. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647 [TBL] [Abstract][Full Text] [Related]
12. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. Jankun J; Merrick HW; Goldblatt PJ J Cell Biochem; 1993 Oct; 53(2):135-44. PubMed ID: 8227186 [TBL] [Abstract][Full Text] [Related]
13. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Xing RH; Mazar A; Henkin J; Rabbani SA Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032 [TBL] [Abstract][Full Text] [Related]
14. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127 [TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667 [TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678 [TBL] [Abstract][Full Text] [Related]
17. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Zannetti A; Del Vecchio S; Carriero MV; Fonti R; Franco P; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M Cancer Res; 2000 Mar; 60(6):1546-51. PubMed ID: 10749121 [TBL] [Abstract][Full Text] [Related]
18. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639 [TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator system and breast cancer (Review). Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776 [TBL] [Abstract][Full Text] [Related]
20. Tissue urokinase-type plasminogen activator receptor levels in breast cancer. Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]